Clinical trial · Interventional
Intrahepatic Chemotherapy to Patients With Non-resectable Liver Metastases From Solid Tumor
Intrahepatic and Systemic Chemotherapy Together With Antibody to Patients With Non-resectable Liver Metastases From Solid Tumors
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to see if treatment with intrahepatic chemotherapy is a good options in patients with liver metastases. If the patients have colorectal cancer and never had got chemotherapy the investigators will use oxaliplatin together with capecitabine. If the patient is K-RAS wild type the investigators will add cetuximab. In patients who had received oxaliplatin or in patients with other cancers the investigators will use mitomycin and gemcitabine together with capecitabine.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Liver Metastasis | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Mitomycin + Gemcitabine | Drug | — | UNRESOLVED |
| Oxaliplatin | Drug | Oxaliplatin | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Mitomycin+Gemcitabine
- description
- Intrahepatic treatment, where all standard treatments have been used
- interventionNames
- Drug: Oxaliplatin
- Drug: Mitomycin + Gemcitabine
Primary outcomes (1)
- measure
- tumor response according to RECIST 1.1. Number of patients with CR, PR, SD and PR will be recorded.
- timeFrame
- 5 years
Secondary outcomes (1)
- measure
- Progression free survival, adverse events
- timeFrame
- 5 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * liver metastasis * solid tumor Exclusion Criteria: * poor performance
References
Publications (0)
Data not yet available